- OLE study - Open Label Extension study phase Clarinet with lanreotide Autogel 120 mg in metastatic enteropancreatic neuroendocrine tumors2016 | First Faculty of Medicine
- Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone2011 | First Faculty of Medicine
- Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future2010 | First Faculty of Medicine
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension2010 | First Faculty of Medicine
- Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS studyPublication without faculty affiliation
- Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study2016 | Faculty of Medicine in Pilsen
- Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study2021 | First Faculty of Medicine
- Contemporary options and perspectives in the treatment of acromegaly2014 | First Faculty of Medicine
- Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumoursPublication without faculty affiliation
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study2016 | First Faculty of Medicine
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors2020 | First Faculty of Medicine
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors2014 | First Faculty of Medicine
- A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues2017 | First Faculty of Medicine
